Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 44.66% is 34% below its 5-year average of 68.06%, near the low end of its 5-year range (26.62%–106.25%).
As of the fiscal period ended Tuesday, June 30, 2026. 34.90% below its 12-month average of 68.60%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 44.66%.
DEBT TO ASSETS RATIO
44.66%
DEBT TO ASSETS RATIO AVG TTM
68.60%
DEBT TO ASSETS RATIO AVG 3Y
55.56%
DEBT TO ASSETS RATIO AVG 5Y
68.06%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-34.90%
CURRENT VS 3Y AVG
-19.61%
CURRENT VS 5Y AVG
-34.38%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 669 covered companies
CURRENT VS SECTOR MEDIAN
+44561.02%
vs the sector median at left
Aquestive Therapeutics, Inc.
Market Cap
$572.98M
Debt to Assets Ratio
44.66%
TTM Avg
68.60%
3Y Avg
55.56%
5Y Avg
68.06%
Market Cap
$569.29M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$584.33M
Debt to Assets Ratio
0.18%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$560.60M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$560.00M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$555.99M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$594.43M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$551.43M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | $572.98M | 44.66% | 68.60% | 55.56% | 68.06% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $569.29M | 0.01% | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $563.68M | 0.16% | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $584.33M | 0.18% | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $560.60M | 0.00% | N/A | N/A | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $555.99M | 0.19% | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $594.43M | 0.01% | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $551.43M | 0.00% | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.84M | 1.39% | N/A | N/A | N/A |
Debt/Assets
44.7%
Debt/Equity
N/A
Current Ratio
7.19
Interest Coverage
-4.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 44.66% |
| 2026-03-31 | 94.65% |
| 2025-12-31 | 81.94% |
| 2025-09-30 | 78.79% |
| 2025-06-30 | 42.97% |
| 2025-03-31 | 38.28% |
| 2024-12-31 | 37.47% |
| 2024-09-30 | 33.53% |
| 2024-06-30 | 30.38% |
| 2024-03-31 | 26.62% |
| 2023-12-31 | 58.03% |
| 2023-09-30 | 75.76% |
| 2023-06-30 | 79.17% |
| 2023-03-31 | 79.02% |
| 2022-12-31 | 100.73% |
| 2022-09-30 | 106.25% |
| 2022-06-30 | 99.42% |
| 2022-03-31 | 100.62% |
| 2021-12-31 | 91.01% |
| 2021-09-30 | 66.54% |
| 2021-06-30 | 63.49% |
| 2021-03-31 | 66.98% |
| 2020-12-31 | 64.37% |
| 2020-09-30 | 130.51% |
| 2020-06-30 | 102.97% |
| 2020-03-31 | 100.73% |
| 2019-12-31 | 76.88% |
| 2019-09-30 | 122.44% |
| 2019-06-30 | 94.10% |
| 2019-03-31 | 70.01% |
| 2018-12-31 | 54.35% |
| 2018-09-30 | 52.00% |
| 2018-06-30 | 116.54% |
| 2018-03-31 | 99.75% |
| 2017-12-31 | 105.55% |
